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1. Introduction
For the past two decades, the mortality rate has steadily 
declined for certain cancers (lung, prostate, colon, and breast), 
yet has changed very little for others (ovarian, pancreatic, liver, 
stomach, uterine, leukemia, and bladder).[1] The latter group 
suffers a notable lack of noninvasive early detection method-
ologies, leaving few treatment options for patients diagnosed 
All cells expel a variety of nanosized extracellular vesicles (EVs), including 
exosomes, with composition reflecting the cells’ biological state. Cancer 
pathology is dramatically mediated by EV trafficking via key proteins, lipids, 
metabolites, and microRNAs. Recent proteomics evidence suggests that 
tumor-associated exosomes exhibit distinct expression of certain membrane 
proteins, rendering those proteins as attractive targets for diagnostic or thera-
peutic application, yet it is not currently feasible to distinguish circulating EVs 
in complex biofluids according to their tissue of origin or state of disease. Here, 
peptide binding to tumor-associated EVs via overexpressed membrane protein 
is demonstrated. It is found that SKOV-3 ovarian tumor cells and their released 
EVs express α3β1 integrin, which can be targeted by the in-house cyclic 
nonapeptide, LXY30. After measuring bulk SKOV-3 EV association with LXY30 
by flow cytometry, Raman spectral analysis of laser-trapped single exosomes 
with LXY30-dialkyne conjugate enables the differentiation of cancer-associated 
exosomes from noncancer exosomes. Furthermore, the foundation for a highly 
specific detection platform for tumor-EVs in solution with biosensor surface-
immobilized LXY30 is introduced. LXY30 not only exhibits high specificity 
and affinity to α3β1 integrin-expressing EVs, but also reduces EV uptake into 
SKOV-3 parent cells, demonstrating the possibility for therapeutic application.
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at an advanced stage. Fortuitously, all cells 
expel extracellular vesicles (EVs), whose 
biomolecular contents reflect the com-
position and state of their parent cells.[2] 
A nanosized subset of these vesicles, 
termed exosomes, holds great promise for 
cancer diagnostics, and can be detected 
in numerous biofluids, including blood, 
urine, saliva, ascites, and cerebrospinal 
fluid.[3–5]
Tumor cells can highjack the exosomal 
pathway for means of immunosuppres-
sion, antigen presentation, tumor growth, 
and metastasis.[6–9] It has been demon-
strated that proteins, genes, lipids, and 
metabolites exhibit distinct profiles within 
exosomes derived from tumor cells com-
pared to healthy cells.[10,11] Combined with 
the cell’s ability to quickly alter EV compo-
sition in response to stimulus (e.g., stress, 
pathology, and drug treatment), exosomes 
have been implicated as vast mediators 
of intercellular communication, and pro-
vide a framework for diagnostic platform 
development. Much work is currently 
underway to develop methods for exploiting the chemical con-
tent trafficked in tumor-associated exosomes for use as potent 
biomarkers.[12–17]
An ideal point-of-care isolation strategy for cancer diagnos-
tics would address two issues: first, tumor-associated EV sub-
populations represent only a small fraction of the circulating 
secretome, thus the nontumor EV background impedes sen-
sitive detection. Second, tumor EVs should be distinguished 
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from nontumor EVs. One potential approach for simple, rapid 
discrimination of tumor EVs is to exploit differences in their 
surface composition. Many membrane proteins have been 
identified to be generally associated with exosome-type EVs 
(CD9, CD63, CD81, and EpCAM).[18] Others have been reported 
to be enriched in certain tumor-associated exosomes, such as 
EGFR and HER2.[19,20] Given that several recent studies have 
demonstrated enrichment of particular integrins in exosomes 
derived from a variety of tumor cells, exosomal integrins are 
interesting potential targets.[21–26]
Integrins are transmembrane heterodimer glycoproteins 
composed of an α and β subunit, and contribute to a variety 
of normal and pathogenic biological processes including cell 
adhesion, inflammation, thrombosis, metastasis, and adhesion-
mediated drug resistance.[27] Characteristic combinations of 
integrins are often overexpressed in certain tumor cells.[27] In 
2015, Hoshino et al. described that organotropic tumor metas-
tasis is largely mediated via exosomal integrin trafficking.[9] 
They demonstrated that exosomes expressing integrins α6β4 
and α6β1, or αvβ5, contributed to metastatic spreading toward 
the lung or liver, respectively, and that prior “education” with 
lung-tropic exosomes (by retro-orbital injection in mice) redi-
rected metastasis of bone-tropic tumor cells to the lung.[9] Fur-
thermore, targeting of the α6β4 or αvβ5 integrins decreased 
metastasis.[9] Thus, EV-expressed integrins represent an attrac-
tive target for both (i) diagnostic discrimination of circulating 
tumor EVs and (ii) therapeutic application by binding tumor EV 
integrins in order to block their tumorigenic function.
Recent work in our lab has led to the discovery of sev-
eral unique ligands capable of binding tumor cells through 
their overexpressed integrins, including ligands against 
α3β1,[28,29] α4β1,[30] and αvβ3.[31] These ligands were found by 
screening tumor cells against focused combinatorial libraries 
of peptide or peptidomimetic molecules, via the one-bead 
one-compound (OBOC) combinatorial library approach.[32,33] 
One motif in particular, [c(d/D)GXGXXc] (where d-amino 
acids are lowercase and X represents a randomized position), 
generated several lead peptide ligands with specific binding 
to α3β1 integrin-expressing ovarian adenocarcinoma, glio-
blastoma, and metastatic breast cancer.[28] The best of these 
lead ligands, termed LXY1 [cdGLG-Hyp-Nc] (where Hyp is 
hydroxyproline),[29] was further optimized through struc-
ture–activity relationship studies and a more focused OBOC 
combinatorial library. This generated the highly potent cyclic 
disulfide-containing peptide: LXY30 [cdG-Phe(3,5-diF)-G-Hyp-
NcR].[34] LXY30 showed increased in vitro and in vivo tumor 
targeting across a panel of ovarian, breast, brain, and nonsmall-
cell lung carcinoma (NSCLC) cells. Furthermore, the binding 
specificity of LXY30 to the α3 integrin subunit was confirmed, 
since binding to α3-expressing U-87MG cells could be inhibited 
by preincubation of the cells with anti-α3 antibody.[34] Finally, 
a scrambled version of LXY30 (scr-LXY30: [cGd-Hyp-Phe(3,5-
diF)-G-NcR]), featuring switched positions of some amino acids 
in the peptide sequence, did not significantly bind to α3β1 inte-
grin-expressing cells, demonstrating the sequence specificity of 
LXY30.[34]
Here, we describe the characterization of the α3β1 integrin-
binding peptide LXY30 with respect to binding exosomes 
derived from α3β1-expressing ovarian tumor cells. Through a 
combination of bulk and single EV characterization techniques, 
we demonstrate that LXY30 exhibits high binding affinity 
to specific tumor cell-derived exosomes, likely via the overex-
pressed α3β1 integrin.
2. Results
2.1. Exosome Isolation and Characterization
Exosomes isolated from SKOV-3 ovarian tumor cells overex-
pressing α3β1 integrin, Jurkat leukemia cells overexpressing 
α4β1 integrin, and healthy human plasma were compared in 
this study. Classic ultracentrifugation (UC) methodology was 
used to isolate EVs from both cancer cell culture superna-
tant (see the Experimental Section for full detail) and human 
plasma samples.[35] The collected EVs were confirmed as 
exosomes by employing the International Society for Extracel-
lular Vesicles (ISEV) suggested standards[36] for minimal char-
acterization (Figure 1). Thus, western blot (WB) supported 
both the presence of multivesicular body-associated proteins 
CD63, CD9, and tsg101, and also the absence of endoplasmic 
reticulum-associated protein calnexin (Figure 1a). Imaging by 
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Figure 1. Confirmation of exosome type for vesicles isolated from SKOV-3 ovarian tumor cells. a) Western blot analysis for CD63, CD9, tsg101, calnexin, 
and α3 and β1 integrin subunits in SKOV-3 cell lysate (CL) and exosome (Exo) preparations (20 µg protein per lane). b) Electron microscopy image of 
exosomes by negative-stained conventional EM showing the typical cup -hape morphology. c) AFM amplitude image of isolated exosomes deposited 
on mica. d) Exosome number concentration and size distribution by NTA, with red bars representing one standard deviation.
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negative-stained electron microscopy (EM) demonstrated typ-
ical exosome size and “cup-shape” morphology (Figure 1b).[36] 
Atomic force microscopy (AFM) provided complementary size 
measurement (Figure 1c). Nanoparticle tracking analysis (NTA) 
was used to determine EV concentration (1.70 ± 0.11 × 1013 par-
ticles mL−1) and size distribution (177 ± 87 nm) (Figure 1d). 
According to a recently reported metric to assess exosome 
purity, we measured the ratio of protein concentration to par-
ticle number concentration to be 2.6 × 109 particles µg−1 pro-
tein, confirming that our isolation procedure reliably purified 
exosomes from excessive protein contamination.[37]
2.2. On-Bead Flow Cytometry
To confirm cell–peptide binding, LXY30 (Figure 2a) and scr-
LXY30 were labeled with fluorescein isothiocyanate (LXY30-Fl) 
dye via PEG2 spacer at the peptide N-terminus and incubated 
with SKOV-3 cells. As previously reported, SKOV-3 cells exhib-
ited high affinity for LXY30-Fl but only minimal affinity for the 
scrambled analogue (Figure 2c, left panel).[34] Next, SKOV-3 
exosomes were premixed with either LXY30-Fl or scr-LXY30-
Fl overnight. After purification from unbound ligand by cen-
trifugal filtration, exosomes were mixed with the latex beads 
(Figure 2b). Similar to the cells, flow cytometry revealed a sig-
nificant increase in fluorescence intensity for exosomes bound 
to LXY30-Fl compared to the scrambled-LXY30-Fl (Figure 2c, 
right panel) (statistical significance of p < 0.01). On the other 
hand, α4β1-expressing Jurkat tumor cells and 
their released exosomes bound LXY30-Fl and 
scr-LXY30-Fl to a similar, minimal extent 
(data not shown). When incubated with anti-
α3-Fl, SKOV-3 cells demonstrated a high 
degree of binding, yet bead-bound SKOV-3 
exosomes showed little increase in fluores-
cence compared to the control. In addition to 
the Jurkat cell-derived exosome control that 
tested the specificity of our peptide LXY30 
toward its expected α3β1 integrin target, we 
also tested exosomes isolated from healthy 
human plasma samples. Following ultracen-
trifugation isolation (see the Experimental 
Section for full detail), the plasma-derived 
exosomes were subjected to LXY30-Fl and 
scr-LXY30-Fl binding and examination by 
on-bead flow cytometry (Figure 2c, dotted 
lines). The healthy human-plasma-derived 
exosomes did not exhibit significant binding 
to either LXY30-Fl or scr-LXY30-Fl peptide.
On-bead flow cytometry is limited to meas-
uring bulk exosomes, and therefore may not 
be sensitive enough to distinguish circulating 
tumor-associated EVs. While single exo-
some flow cytometry is becoming feasible, 
it is still presently too unreliable for timely 
reporting of our findings. We therefore devel-
oped a new Raman spectroscopic method to 
measure LXY30-exosome binding for single 
vesicles.
2.3. Laser Tweezers Raman Spectroscopy (LTRS)
We employed LTRS to measure the binding of LXY30 to single 
vesicles by analyzing variations in Raman-active peaks for opti-
cally trapped vesicles, via adaptation of our previously reported 
methodology for single vesicle LTRS.[38] As the ISEV-suggested 
characterization framework[36] becomes more difficult to apply 
on a single-vesicle basis, here we refer to the optically trapped 
vesicles more generally as EVs.
For determining the extent of ligand binding to single EVs, 
LXY30 and scr-LXY30 peptides were each covalently function-
alized with a highly Raman-active compound: 4-(phenylbuta-
1,3-diyn-1-yl)benzoic acid (RT, for Raman Tag). In a region 
typically empty of Raman chemical shifts for unlabeled EVs, 
the di-alkyne and aromatic bonds present in the RT give rise 
to strong Raman shifts at 1600 and 2230 cm−1, respectively 
(Figure 3, blue trace). EV samples were incubated with LXY30-
RT or scr-LXY30-RT (1 × 10−6 m) for optical tweezers trapping 
and Raman spectra measurement by LTRS. For each condition, 
at least ten individual EVs with sizes in the range of 80–200 nm 
were trapped and their Raman spectra averaged over 5 min. 
Typical peaks were indicative of EV trapping, for example, the 
peak centered at 1066 cm−1 can be assigned to CC stretching 
in lipids, the peak at 1450 cm−1 assigned to CH2 and CH3 
deformations in proteins and lipids, and the peaks at 1651 
and 1668 cm−1 as CC stretching in lipids and protein amide 
Adv. Biosys. 2017, 1, 1600038
Figure 2. On-bead flow cytometry (FC). a) Chemical structure of the LXY30 peptide. For FC 
measurement, the N-terminus of the peptide is coupled to a FITC dye molecule via PEGylated 
spacer. b) Exosomes tagged with fluorescently labeled antibody or peptide are bound to sulfate/
aldehyde-coated latex beads for FC measurement. c) FC profiles of fluorescence-labeled LXY30 
(green), scr-LXY30 (red), and anti-α3 (blue) binding to SKOV-3 cells (left) or exosomes (right). 
Exosomes from healthy human plasma showed limited binding to scr-LXY30 (dotted red) and 
LXY30 (dotted green).
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I vibrations, respectively.[38] Effectively at the same dilution, 
the LXY30-RT peptide alone was undetectable (the spectra 
presented in Figure 3a are far more concentrated), yet when 
condensed on the vesicle could be observed quite strongly, as 
evident by the emergence of the two characteristic RT peaks 
(Figure 3b). Incubation with scr-LXY30-RT resulted in little 
discernible binding, and furthermore control Jurkat exosomes, 
which lack α3β1, were not detected to measurably bind LXY30-
RT. For trapped exosomes isolated from healthy human plasma, 
too, we could not detect any binding to LXY30-RT or scr-LXY30-
RT. To quantify the relative binding stoichiometry of LXY30-
RT to a single SKOV-3 vesicle, we further examined the region 
between 1550 and 1700 cm−1 (Figure 4). This region contains 
two major peaks, Peak A, centered at 1600 cm−1 arising from 
the Raman tag’s aromatic/di-alkyne func-
tional group, and Peak B, the group of peaks 
arising from the aforementioned exosome 
protein/lipid content. The ratio of these 
peaks was taken for absolute comparison of 
chemical contribution from either the RT 
or the exosome. For this comparison, the 
Raman intensities were not normalized. We 
observed that the peaks did not scale together 
(Figure 4b), indicating that total protein con-
tent and LXY30 binding were not linearly 
correlated.
2.4. Effect of LXY30-Binding on Cell Uptake
Following demonstration of specific binding 
of LXY30 peptide to SKOV-3 cells and 
their derived exosomes, we tested whether 
LXY30-binding could inhibit or otherwise 
affect cell uptake of SKOV-3 exosomes. For 
visualization by confocal laser scanning microscopy (CLSM), 
isolated SKOV-3 exosomes were nonspecifically labeled with 
the red fluorescent lipophilic dye, 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI). DiI-labeled 
SKOV-3 exosomes were incubated with cells for 1 h before 
washing and cell imaging by CLSM (Figure 5). Prior to pep-
tide binding, exosomes exhibited significant uptake in SKOV-3 
cells, with punctate fluorescence patterning indicative of endo-
cytic uptake (Figure 5c). Energy-dependent uptake of SKOV-3 
exosomes by SKOV-3 cells has been previously reported.[39] 
When scr-LXY30 (1 × 10−6 m) was preincubated with DiI-
labeled SKOV-3 exosomes (and unbound peptide removed 
by centrifugal spin columns), we observed a significant 
(p < 0.005) decrease in uptake (Figure 5d). Preincubation with 
LXY30 at the same concentration significantly reduced uptake 
even compared to the scr-LXY30 case (p < 0.005) (Figure 5e). 
Increasing LXY30 concentration continued reducing uptake 
until 10 × 10−6 m, at which point further increase of concentra-
tion did not continue to increase prohibition of exosome uptake 
(Figure 5f). Furthermore, at incubation concentrations above 
10 × 10−6 m, significant cell toxicity occurred. CLSM images 
were quantified by pixel intensity and normalized by cell area 
for statistical comparison (Figure 5a).
2.5. Capture of SKOV-3 EVs by Surface Immobilized LXY30
To assess the potential of immobilized LXY30 as a tumor-
associated exosome capturing or detection agent, we applied 
multiparametric surface plasmon resonance (MP-SPR). While 
SPR has been recently applied to EV characterization, these 
reports were performed using surface-immobilized antibodies 
targeted against surface proteins of vesicles, for instance, anti-
CD9 or anti-CD63.[40] Since most types of EVs express such 
generic membrane proteins in their membrane surfaces, they 
are unable to distinguish between tumor and healthy EVs. 
Instead, in this proof-of-concept model system, we demonstrate 
that immobilized LXY30 peptide on an SPR chip surface could 
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Figure 4. a) Representative Raman spectra (without normalization) for 
single vesicles mixed with LXY30-RT peptide. In this wavenumber region, 
peaks originate either from the LXY30-RT (centered near 1600 cm−1) or 
from the exosomal contents (amide region centered near 1650 cm−1). 
Spectra are colored and numbered for ease in comparison. Gaussian 
curve fitting was used to distinguish peak A from peak B and obtain peak 
heights (e.g., spectra no. 2 is plotted above the raw data). b) Measured 
heights of peak A and peak B for each spectrum, and their ratios, listed in 
descending order by peak B height. The ratios are not constant, indicating 
that stoichiometry may not be fixed across exosome size as might be 
expected, and moreover varies widely from vesicle to vesicle.
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Figure 3. Laser tweezers Raman spectroscopy (LTRS) of SKOV-3 EV binding to Raman-tagged 
LXY30. Top: Normalized Raman spectra for LXY30-RT peptide. Bottom: Raman spectra for 
SKOV-3 EVs before (green) and after (red) LXY30-RT addition. When the spectra are overlaid, 
two prominent peaks indicative of the chemical shifts for the Raman tag become apparent 
(highlighted in yellow). The solid line and shaded area represent the average +/- one standard 
deviation.
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capture the tumor EVs, and furthermore, that the surface-asso-
ciated biolayer of captured EVs can be characterized for average 
thickness (d) and refractive index (n). Moreover, by comparing 
the recorded shifts in the position of SPR peak minimum 
reflectance (ΘSPR), interaction kinetics for peptide–EV binding 
can be calculated, including association/dissociation rate con-
stants (ka/kd) and total binding affinity (KD).
Figure 6 illustrates the MP-SPR scheme and relevant 
sensorgrams following EV injection. Several solutions are 
sequentially introduced by flowing over chips precoated with 
a self-assembled monolayer (SAM) of biotinylated-alkanethiol 
(11-mercapto-1-undecanol, MuOH). The MP-SPR instrument 
used here features two independent channels for parallel chip 
functionalization. To both channels, streptavidin was flown 
over and bound to the biotinylated surface, as confirmed by 
SPR response (Figure 6b). To flow channel 1 (Figure 6b, black), 
LXY30-biotin was added (in increasing concentration to ensure 
complete surface coverage), while control flow channel 2 
(Figure 6b, red) was not exposed to LXY30-biotin. The subse-
quent injection of SKOV-3 exosomes in both channels at 100 
min resulted in characteristic adsorption in the case of LXY30-
decorated surface (flow channel 1) but little to no exosome 
binding for the control without LXY30-biotin (flow channel 2).
To assist modeling the kinetic parameters of binding, 
exosomes were serially injected at three different concentra-
tions, representing 50×, 30×, and 10× dilutions (3.4 × 109, 5.7 × 
109, and 1.7 × 1010 particles mL−1, respectively). The sequential 
injections produced a stepwise signal reflecting the steady-state 
binding of exosomes at the sensor surface, corresponding to the 
three peaks evident in the flow channel 1 (Figure 6b outlined 
boxes, and examined more in detail in Figure 7a). For modeling 
the interaction kinetics, we employed a two-site binding model 
(the relevance of this model is discussed in the following sec-
tion) allowing for two instances of LXY30 ligand binding to a 
single vesicle. For three hypothetical cases where the integrin 
content at the exosome surface represents either (i) 1%, (ii) 5%, 
or (iii) 10% of the total protein per particle, the α3β1 integrin 
concentration can be estimated. Hence, using the total protein 
(0.65 µg µL−1) concentration, the initial particle concentration 
determined with the NTA (1.7 × 1014 particles L−1), and the 
average molecular mass for a single α3β1 complex (220 kDa), we 
estimated the α3β1 integrin concentrations as listed in Table 1. 
These values were used to fit the model to the data for the three 
injected concentrations. The resulting interaction kinetics eval-
uation yielded two association rate constants, ka1 and ka2, two 
dissociation rate constants kd1 and kd2, and two binding affini-
ties, KD1 and KD2, respectively, for the possible cases (i), (ii), and 
(iii), as represented in Table 2. The results for binding affinities, 
KD1 varied in the range of 12–26 × 10−9 m, and KD2 between 55 
and 480 × 10−12 m, suggest strong binding of SKOV-3 exosomes 
to the surface-bound LXY30 ligands. The low chi-squared 
values indicate that the data fitting was accurate. This can also 
be observed in Figure 7a displaying the measured (solid black 
Adv. Biosys. 2017, 1, 1600038
Figure 5. Effect of LXY30-binding on cell uptake. a) Quantification of exo-
some uptake between conditions by measuring the mean fluorescence 
intensity (MFI) per SKOV-3 cell in representative CLSM images. b) CLSM 
control image of SKOV-3 cells with no DiI-labeled exosomes added. The 
remaining images represent the conditions where DiI-labeled exosomes 
were added to cells after premixing with c) no peptide, d) 1 × 10−6 m scr-
LXY30, e) 1 × 10−6 m LXY30, and f) 10 × 10−6 m LXY30. The scale bar is 
20 µm. * represents p < 0.005.
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line) and calculated data (dotted lines) converging relatively 
well, and, furthermore, the calculated data appear independent 
of our assumption for protein coverage (1%, 5%, 10%).
The full angular SPR spectra (between 40° and 78°) before 
and after exosome adsorption (Figure 7b) was used to model 
adsorbed thickness (d) and refractive index (n) of the biolayer 
formed by the surface-bound SKOV-3 exosomes (displayed in 
Table 2). The layer modeling is based on the two-wavelength 
method,[41,42] but for clarity Figure 7b displays only the 670 nm 
laser data and the last phase of layer modeling is illustrated, 
that is, the intermediate steps of layer modeling are omitted. 
The SPR peak minimum position undergoes an evident change 
from smaller angular values toward larger as the streptavidin 
and subsequent concentration series of SKOV-3 exosomes are 
associating to the surface. The refractive index of the resulting 
exosome layer was modeled at n = 1.341, slightly higher than 
the approximate refractive index of an aqueous buffer solution, 
n = 1.334. This was expected given the presence of light 
refracting compounds such as proteins, lipids, and nucleic 
acids in the exosomes. The mass of bound SKOV-3 exosomes 
per sensor surface unit area (ng cm−2) and the average height 
of the resulting exosome layer can also be estimated, based on 
calculation of surface mass density (Γ) increase yielded by the 
binding exosomes. First, the de Feijter equation and refractive 
index increment dn/dc = 0.182 cm3 g−1 are used to determine 
the dependency between the observed change in SPR peak min-
imum shift and the amount of mass adsorbed on the surface.[43] 
For the employed SPR system, we obtain a conversion factor: 
∆1 mdeg = ∆(Γ) ≈ 0.6 ng cm−2. Thus, an estimate of ≈90 ng cm−2 
was calculated for surface mass density increase, with an average 
layer thickness of 34 nm, despite the size distribution of SKOV-3 
exosomes to be measured by NTA at 177 ± 5.4 nm. Possible 
explanations for this observation 
are proposed in the following 
section.
3. Discussion
Of the α3β1 integrin-expressing 
tumor cell lines found to bind 
LXY30 in preliminary studies, 
SKOV-3 ovarian tumor cells reli-
ably produced the largest number 
of EVs with minimal effort in 
cell maintenance, and thus were 
chosen as the model cell line for 
this study. Jurkat human T lym-
phoid tumor cells were cultured 
as a control to measure integrin 
specificity, since they express 
α4β1 and not α3β1. Using western 
blot on SKOV-3 cell and SKOV-3 
exosome lysates, we measured 
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Figure 6. On-chip capture of tumor EVs. a) MP-SPR detection platform for tumor SKOV-3 exosomes using the surface-immobilized LXY30 capturing 
peptide. Each step of the peptide immobilization via streptavidin-biotin conjugation can be followed by SPR response. b) Sensorgram of the SKOV-3 
exosome detection following biotin-PEG-SH self-assembled monolayer (SAM) formation. First, streptavidin was injected to both flow channels, fol-
lowed by injections of LXY30-biotin in flow cell 1 only. Finally, SKOV-3 exosomes were injected to both flow channels. The characteristic adsorption 
outlined by the dotted box was modeled for extraction of kinetic parameters (Figure 7).
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Figure 7. Kinetic modeling of MP-SPR sensorgrams. a) The solid black line shows the measured data during 
the three injections while the red, blue, and pink dashed lines depict the fitted data for the hypothesized 
cases of (i) 1%, (ii) 5%, and (iii) 10% coverage of α3β1 integrin on the surface of a SKOV-3 exosome. b) Full 
SPR angular spectra recorded at various time points during the experiments; the black line represents the 
initial situation whereby the gold sensor surface and SAM layer were measured; the red line illustrates the 
events after the streptavidin injection and the following baseline stabilization; and the blue line is a snapshot 
after all three SKOV-3 concentrations were injected and a stable baseline was observed. The pink dashed line 
depicts the modeled fitting at the last phase of the interactions, that is, following the three SKOV-3 injections.
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the presence of both α3 and β1 integrins (Figure 1a), paving the 
way for targeting tumor-associated exosomes by (i) reproducing 
previous findings that tumor cells pass certain overexpressed 
integrins to their released exosomes,[9] and (ii) identifying a 
target for LXY30 binding. Interestingly, α3 was not readily 
detectable in the SKOV-3 cell lysate compared to the SKOV-3 
exosome lysate, likely because it represents only a minor frac-
tional component of the total loaded protein, yet we do dem-
onstrate the presence of the α3 subunit on SKOV-3 cells via 
significant anti-α3 antibody binding to SKOV-3 cells when 
examined by flow cytometry (Figure 2c).
Flow cytometry is an increasingly important tool for EV 
characterization.[44] Presently, exosomes themselves are too 
small to be easily and reliably examined by most flow cytom-
eters, but they can be bound to 4 µm aldehyde/sulfate-coated 
latex beads for analysis (Figure 2b). The aldehyde functional 
groups can be covalently linked to lysine side chains on exo-
somal protein while the anionic sulfate groups confer colloidal 
stability to the beads during exosome binding. With this tech-
nique, we found that both α3β1-expressing SKOV-3 tumor cells 
and their released exosomes bind strongly to LXY30-Fl. When 
incubated with scr-LXY30-Fl, SKOV-3 cells exhibited a drastic 
reduction in binding, while their exosomes retained some 
nonspecific binding. Yet, SKOV-3 exosomes did not measur-
ably bind anti-α3 antibody, nor did prior incubation with anti-
α3 inhibit LXY30 binding. This finding could be interpreted by 
considering the state of the integrin membrane protein under 
extreme membrane curvature, as is the case for nanoscale vesi-
cles. At this scale, a biomembrane’s extreme geometrical curva-
ture can critically influence biochemical properties, with some 
reports suggesting occurrence of significant protein conforma-
tional changes.[45] We hypothesize that this may result in poor 
antibody affinity for exosomal integrins, despite high affinity 
toward cell membrane integrins. This point will be investigated 
further in future studies, but is a good example of an advantage 
of peptide binding in place of immunoaffinity methods.
Following bulk flow cytometry measurement of LXY30-EV 
binding, we applied our recently reported technique of LTRS. 
A complete discussion of the application of LTRS to optically 
trap and subsequently measure the chemical composition of 
EVs can be found in our recent publication.[38] While a major 
advantage of Raman spectroscopy is label-free characterization, 
we strengthened the technique with the addition of Raman tags, 
extending the capability of LTRS to measuring ligand binding on 
a single exosome. As illustrated in Figure 4b, ligand binding can 
be quantified in a particular region where spontaneous Raman 
scattering peaks arise from either the LXY30-RT (Peak A, alkyne, 
1600 cm−1) or exosomes (Peak B, a grouping of 1651 cm−1 from 
CC stretching, and 1668 cm−1 from amide I vibrations). The 
table in Figure 4b lists the spectra by descending vesicle peak 
height (Peak B), and it is evident that the ratio of Peak A to 
Peak B fluctuates randomly. In other words, for a given single 
vesicle (i.e., a single trace in Figure 4a), the peaks did not scale 
together, as might be expected if one assumes that Peak B repre-
sents relative exosome amount (protein/lipid content) and that 
integrin number scales with vesicle size. This may represent 
a varied expression in integrin distribution across subpopula-
tions of vesicles that may not scale with vesicle surface area, 
or instead, variation in LXY30–integrin binding. Although we 
could not extract binding stoichiometry in this case, we regard 
Raman tagging of small molecules as a major innovation for 
examining binding to single extracellular vesicles.
Interestingly, LXY30 binding was able to inhibit cell uptake 
of the SKOV-3 exosomes by their parent cells. By premixing DiI-
labeled SKOV-3 EVs with LXY30, we observed a reduction in 
cell uptake up to ≈80%. Preincubation with scr-LXY30 reduced 
uptake by ≈50%, corroborating our flow cytometry results that 
some weak binding of scr-LXY30 still occurs, though signifi-
cantly reduced (p < 0.005) compared to LXY30. Some fluores-
cence was still observed even at saturation of LXY30 (i.e., higher 
amount of LXY30 did not further decrease uptake), indicating 
that even by blocking the α3β1-mediated uptake, some other 
independent mechanisms remain intact. The mechanisms by 
which integrin blocking reduces cell uptake are unclear, but 
given that circulating tumor exosomes are heavily implicated 
in tumorigenesis, this observation renders LXY30 useful for 
potential therapeutic application, and will be a topic of future 
investigation in our lab.
Several recent studies and reviews have reported on the fea-
sibility of applying extracellular vesicles to therapeutic or diag-
nostic application, emphasizing the importance of developing 
EV marker assays that outperform and/or complement con-
ventional diagnostics.[46–48] In that context, the flow cytometry 
and LTRS methodologies presented above would be challenging 
to adopt in clinical settings. In fact, most traditional exosome 
characterization assays typically rely on various techniques 
requiring labels that alter the biochemical structures of interest, 
or are limited to sampling rate, thus not offering information 
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Table 1. Estimated α3β1 integrin concentrations (×10−9 m).
Exosome dilution 50× 30× 10×
1% coverage 0.62 1.03 3.09
5% coverage 3.09 5.15 15.5
10% coverage 6.20 10.3 30.9
















(i) 1% 5.14 × 105 ± 6.97 × 103 9.35 × 10−3 ± 9.11 × 10−5 1.82 × 10−8 ± 4.23 × 10−10 1.28 × 106 ± 7.28 × 102 7.00 × 10−5 ± 1.88 × 10−5 5.46 × 10−11 ± 1.47 × 10−11 7.52
(ii) 5% 6.32 × 105 ± 1.85 × 104 7.30 × 10−3 ± 1.54 × 10−4 1.16 × 10−8 ± 5.83 × 10−10 2.52 × 105 ± 5.93 × 102 6.05 × 10−5 ± 2.53 × 10−5 2.40 × 10−10 ± 1.01 × 10−10 6.46
(iii) 10% 2.90 × 105 ± 1.86 × 104 7.40 × 10−3 ± 1.26 × 10−4 2.55 × 10−8 ± 2.08 × 10−9 1.26 × 105 ± 6.30 × 102 6.07 × 10−5 ± 2.13 × 10−5 4.82 × 10−10 ± 1.71 × 10−10 6.47
d [nm] n Surface mass density increase [ng cm−2]
34 1.341 ∆ (Γ) ≈ 90
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in real time. One recent review by Lener et al. extensively 
describes the requirements for EV-based therapeutics, out-
lining the challenges in costs, reproducibility, effectiveness, 
throughput, and limit of detection.[48] For those reasons, we 
applied the technique of MP-SPR to measure LXY30 binding. 
MP-SPR is extremely sensitive label-free optical measurement 
method based on detecting plasmonic phenomena enhanced 
by a nearby metal surface. MP-SPR measurements can be 
made in real time, allowing for constant monitoring of interac-
tion events. It also employs a microfluidic flow system enabling 
measurements under steady state or dynamic flow conditions, 
and thus is considered more relevant for characterizing physico-
chemical phenomena in biological environments. Furthermore, 
at their best, plasmonic-based measurements offer at least an 
order of magnitude in increased detection sensitivity compared 
to ELISA or fluorescence-based detection methods,[49] there-
fore it will be an excellent direction to explore in future studies 
examining binding to clinical samples.
Using MP-SPR, we confirmed the ability for SKOV-3 
exosomes to bind to LXY30 modified surfaces. We adopted 
the commonly used one-to-two (1:2) binding model for ana-
lyte adsorption, taken from previous observations that the 
CD63 tetraspanin proteins on exosomal membranes exhibit 
such binding behavior.[14] From a physical standpoint there 
may be more than two binding sites per exosome, but it 
has been observed that the two strongest sites are domi-
nant, and other binding events are typically undetected.[50] It 
is noteworthy that the 1:2 binding model is also applicable 
to binding schemes where heterogeneous immobilization 
of the target (i.e., LXY30) at the surface may have occurred. 
We expect that this is likely the case in our measurements, 
since the modeling resulted in good data fitting as seen by 
visual inspection in Figure 7. The calculated interaction 
kinetics parameters (Table 2) did not show strong depend-
ency on the estimated amount of α3β1 integrin proteins on 
the membranes of SKOV-3 exosomes. This observation may 
suggest that the binding of SKOV-3 exosomes occurs as 
long as there are at least some α3β1 found on the surfaces of 
exosomes available for binding. The results of the layer mod-
eling also suggest that either (i) significant vesicular shape 
deformation events may occur during the exosome binding 
or at the surface after binding, (ii) surface-bound LXY30 cap-
tures exosomes of certain diameter or up to some maximum 
diameter, or more likely that (iii) the coverage of exosomes 
at the surface is uneven. The latter is a technical limitation 
of optical modeling, as mathematical fitting of the measured 
angular SPR spectra to the models by Fresnel’s equations is 
made by averaging over the laser spot area on the gold sensor 
surface, ≈1 mm2 in diameter. Therefore, empty spaces in 
the surface-bound layer under the laser spot would result in 
underestimating the calculated layer thickness and refractive 
index. In recent SPR-vesicle literature, physical models have 
been developed to correlate change of refractive index with 
exosome concentration.[51,52] In those models, both particle 
shape deformation and surface unevenness (due to wide par-
ticle size distribution) were considered. The biolayer thickness 
modeling in this study strengthens those previous observa-
tions, namely, that shape deformation may play a role in exo-
some inter actions and should be taken into account.
While the layer modeling yielded rational results with sat-
isfactory accuracy within the context of this study, and had 
resemblance to other recent investigations,[52] intriguing ques-
tions merit further studies. For example, we plan to examine 
the differences between interaction kinetics and biolayer com-
positions for exosomes from different cell types. A prerequisite 
for such studies is that additional exosome-specific capturing 
ligands are found and synthesized, currently underway. Finally, 
calculation of the limit of detection (LOD) also warrants subse-
quent assays in order to find out the feasibility of this platform 
for early-stage cancer detection by sensing tumor-associated 
exosomes in human biofluids.
4. Conclusions
EVs isolated from various biological fluids are essentially a 
mixture of distinct types of vesicles that have originated from 
various parent cells. Hence, the capability to detect certain types 
of EVs, such as tumor-associated ones, is essential for their 
exploitation as diagnostic agents. Since integrins are known 
to be highly overexpressed on cancer cells, and are trafficked 
to those cells’ released EVs, we developed a methodology for 
characterizing the specific targeting of integrin-binding pep-
tides to cancer cell released EVs. Our in-house peptide, LXY30, 
selectively binds the α3β1 integrin overexpressed on cells com-
prising many types of epithelial cancers, including ovarian 
adenocarcinoma cells. In SKOV-3 ovarian tumor cell released 
EVs (that were determined to be primarily exosome-type), pro-
tein quantification revealed the presence of both α3 and β1 inte-
grin subunits. On-bead flow cytometry was used to characterize 
ensemble LXY30 peptide binding to SKOV-3 exosomes, but 
not other types of Jurkat-tumor-cell-derived exosomes. Laser 
tweezers Raman spectroscopy confirmed that LXY30 peptide 
binding occurs at the single vesicle level. Furthermore, by con-
focal microscopy, we determined that LXY30 could dramatically 
reduce SKOV-3 exosome uptake by their parent cells. Finally, 
we present a convenient and straightforward method to cap-
ture and detect cancerous SKOV-3 exosomes in real time by 
MP-SPR, without a priori labeling. This platform allowed for 
monitoring the interaction kinetics of and biolayer properties of 
SKOV-3 vesicles with the surface-immobilized LXY30 capturing 
ligand. The characterization schemes outlined here, along with 
the first report of a ligand capable of discriminating tumor and 
nontumor EVs, represent major steps in improving the poten-
tial of EVs for nanomedical-based therapeutic and diagnostic 
systems.
5. Experimental Section
Unless otherwise noted, all reagents and materials were purchased 
from Sigma-Aldrich Corp. (St. Louis, MO) and used without further 
purification. Cell lines were purchased from ATCC (Manassas, VA).
Cell Culture: Human ovarian carcinoma SKOV-3 cells were grown in 
McCoy’s 5A media and human T-cell leukemia Jurkat cells were grown in 
RPMI 1640 medium. Each medium was supplemented with FBS (10%), 
penicillin (100 units mL−1), and streptomycin (100 µg mL−1). Cells were 
subcultured (37 °C, 5% CO2) and regularly maintained by splitting upon 
reaching an estimated 80% confluence. Contaminating EVs are found 
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in high concentration in FBS and must be removed before exosome 
collection. In vitro serum-free conditions have been demonstrated 
to increase oxidative stress, leading to generation of unintended 
EV release,[53] therefore it is preferred to deplete FBS of exosomes by 
ultracentrifugation. Typically, 30% FBS (150 mL) in appropriate culture 
medium was loaded in the rotor-type 50.2 Ti (Beckman Coulter, 
polycarbonate bottles, prod. no. 355618) and spun at 100 000×g, 4 °C, 
>18 h. After centrifugation, supernatants were filtered (0.2 µm) and 
diluted with appropriate medium to 10% FBS. Clearing of bovine EVs is 
regularly confirmed by NTA. It was observed that exosome yield began 
to drop significantly if a cell line was grown in prolonged absence of 
EV-depleted FBS, therefore cells past five generations after thawing from 
liquid nitrogen were not cultured.
Ultracentrifugation Isolation: After 48–72 h of incubation with 
EV-depleted medium, cell culture supernatant was decanted and 
subjected to low-speed centrifugation to clear any cells (300×g, 5 min, 
4 °C), dead cells (2000×g, 10 min, 4 °C), and cell debris (10 000×g, 
30 min, 4 °C). The resulting supernatant was centrifuged twice at 100 
000×g, 4 °C, 2 h (rotor type: SW 28 Ti, tubes: thickwall polypropylene), 
dissolving and diluting the pellet in PBS between spins to remove 
contaminating free protein. For every 20 million cells at the time of EV 
harvest, the final exosome-containing pellet was dissolved in sterile 
DPBS (25 µL). Aliquots were stored at −80 °C for up to one month. 
Human plasma was obtained from healthy volunteers and deidentified 
via the UC Davis biorepository for laboratory use. Plasma obtained from 
three different patients (≈0.5–1.0 mL each) was used as controls in 
this study. Whole plasma was subjected to identical ultracentrifugation 
isolation as described above for cell culture supernatant.
Western Blot: All reagents listed by part number in this section 
were purchased from ThermoFisher Scientific. Following exosome 
lysis with RIPA buffer (prod. no. 89900), protein concentration was 
measured by BCA assay (Pierce kit, prod. no. 23225) according to 
manufacturer’s instructions. For WB analysis, exosome aliquots 
containing 20 µg protein (as determined by BCA assay) were lysed in 
SDS sample buffer: 2% (w/v) sodium dodecyl sulfate, 125 × 10−3 m 
Tris-HCl at pH 6.8, 12% (v/v) glycerol, 0.05% (w/v) bromophenol blue, 
and DTT (50 × 10−3 m). For proteins that should not be reduced prior 
to immunostaining (tetraspanins CD9 and CD63), DTT was omitted 
and its volume replaced by PBS. To obtain cell lysates, cell suspensions 
were washed by repeated (3×) pelleting (300×g, 5 min) and dissolution 
in sterile DPBS. After three washes, the cell pellet was dissolved in 
RIPA lysis buffer with protease inhibitor (prod. no. 78420), and briefly 
vortexed before and after 30 min incubation on ice. Following incubation 
the solution was centrifuged to precipitate insoluble membrane 
components and other impurities (18 000×g, 30 min, 4 °C) and resulting 
supernatant frozen for up to six months at −80 °C. Protein aliquots 
(20 µg) were dissolved in Laemmli sample buffer (prod. no. NP0008), 
supplemented appropriately with reducing agent, just prior to gel 
loading. After dissolution in appropriate loading or lysis buffer, EV and 
cell lysates were incubated at (95 °C, 5 min) while shaken (900 rpm) and 
then centrifuged (1 min, 13 000×g).
Gel electrophoresis of lysed EVs or cell was performed by first loading 
samples (20 µg protein/well) onto 4%–12% Bis-Tris ten-well precast 
gels (NuPage Novex, prod. no. NP0335) and filling the electrophoresis 
rig (Xcell Surelock gel tank) with MOPS buffer (Nu-Page, prod. no. 
NP000102). Proteins were separated at 90 V for 30 min, then 120 V 
until complete. The gel was carefully removed, washed with buffer, 
and transferred to nitrocellulose membrane (prod. no. 88018) for 2 h 
at constant current of 400 mA, with the entire WB module submerged 
in ice. The resulting blots were removed and blocked overnight by 
submerging in blocking buffer: 5% (w/v) nonfat dairy milk in Tris-
buffered saline with Tween (TBST) buffer. For immunostaining, primary 
antibody was appropriately diluted in blocking buffer according to its 
datasheet and incubated with blot for 1 h at room temperature while 
gently shaking. The following primary antibodies were used: mouse 
monoclonal anti-CD63 (ThermoFisher Scientific), mouse monoclonal 
anti-CD9 (ThermoFisher Scientific), rabbit polyclonal anti-tsg101 
(Sigma Aldrich, St. Louis, MO), rabbit polyclonal anti-calnexin (Cell 
Signaling Technology, Danvers, MA), and mouse monoclonal anti-α3 
and anti-β1 integrins (Santa Cruz Biotechnology, Dallas, TX). The blots 
were washed (3× TBST, 5 min) and incubated with HRP-conjugated 
secondary antibody diluted in blocking buffer (1:2000) for 1 h. Secondary 
antibodies were goat antirabbit and goat antimouse immunoglobulin 
(Santa Cruz Biotechnology, Dallas, TX). ECL substrate (prod. no. 35050) 
was used to develop blots according to manufacturer’s instructions and 
immunoactive bands detected by chemical imaging (Bio-Rad ChemiDoc 
Hercules, CA). Representative WB for SKOV-3 cell lysate and exosomes 
is shown in Figure 1a.
Electron Microscopy: EVs were contrasted and embedded for whole-
mount EM analysis according to previously reported methods.[35] Briefly, 
fresh EV-containing UC pellets were directly resuspended in 2% (w/v) 
paraformaldehyde in PBS, with 5 µL deposited on Formvar carbon-
coated EM grids. The grids were sequentially floated on several 20–50 µL 
drops for washing (PBS), fixing (glutaraldehyde), contrasting (uranyl 
oxalate), and further contrasting/embedding (uranyl acetate/methyl 
cellulose). Grids were subsequently imaged by EM at 80 kV (Philips 
CM120). A representative EM image of SKOV-3 derived EVs is displayed 
in Figure 1b.
Atomic Force Microscopy: An aliquot (50 µL) of diluted (1:200) purified 
SKOV-3 EVs was pipetted onto a freshly cleaved mica sheet and air 
dried. Images were acquired with an Oxford-Asylum Research MFP-3D 
AFM and K-TEK Nanotechnologies Tetra14 silicon lever with a spring 
constant of about 5. Pixel resolution was 512 × 512 and scan rate was 
0.5 Hz. Topography and Z-sensor images were flattened using mean 
surface data to establish a reference plane. Amplitude images were 
also taken in order to show edge enhancements, approximating the EV 
surface gradient. A representative AFM amplitude image for SKOV-3 EVs 
is shown in Figure 1c.
Nanoparticle Tracking Analysis: NTA was recorded on a NanoSight 
LM10 instrument with illumination at 488 nm. Following dilution of 
purified EVs (1:1000) in triple-filtered PBS, samples were introduced 
by perfusion pump. For a typical experiment, three 60 s videos were 
recorded, with 30 s of sample flow between replicates. Concentration 
was confirmed to be in the acceptable range for NTA analysis 
(3–20 × 108 particles mL−1), or else diluted/concentrated appropriately 
and reanalyzed.
Peptide Synthesis: Solid-phase peptide synthesis was used to synthesize 
LXY30 and scr-LXY30 peptides. Rink amide resin (0.52 mmol g−1 
loading) was chosen as the solid support in order to facilitate peptide 
synthesis and eventual cleavage from the resin. HPLC (high-performance 
liquid chromatography) grade dimethylformamide (DMF) was used for 
coupling and analytical reagent grade DMF, dichloromethane (DCM), 
and methanol (MeOH) were used for washing of the resin throughout 
synthesis. Resin was swollen overnight in DMF in a polypropylene column 
with frit and tight-sealing cap, enabling easy washing via bead retention 
between coupling steps. The protecting Fmoc group was removed from 
the resin by 20% (v/v) 4-methyl piperidine/DMF solution (2 × 15 min), 
and the resin was washed by DMF (15 mL × 3), MeOH (15 mL × 3), 
and DCM (15 mL × 3). Standard Fmoc/t-But peptide chemistry was 
used to couple the amino acids to the resin. For each coupling step, 
5 molar eq. of COMU ((1-cyano-2-ethoxy-2-oxoethylidenaminooxy)
dimethylamino-morpholino-carbenium hexafluorophosphate) and 
10 molar eq. DIEA (N,N-diisopropylethylamine) were added with 5 molar 
eq. of Fmoc-protected amino acid. After 1 h of light agitation, Kaiser 
test was used to confirm complete reaction. Following coupling, the 
Fmoc group was again removed by 4-methyl piperidine/DMF solution, 
confirmed by Kaiser test. Prior to cleavage from the bead, the disulfide 
in the peptide was formed. Iodine (8 molar eq. to resin, dissolved in 
DCM) was used to simultaneously deprotect trityl chemical groups on 
the cysteine residues and oxidize the thiols to form a ring. The resin was 
subsequently washed with copious DMF and aqueous ascorbic acid to 
quench and remove excess iodine. Finally, the resin was mixed for 3 h 
with slight agitation at room temperature with a cleavage cocktail (82.5% 
trifluoroacetic acid, 5% thioanisole, 5% water, 5% phenol, and 2.5% 
triisopropylsilane, all % are v/v), resulting in both removal of side chain 
protecting groups and cleavage from the resin. The peptide-containing 
Adv. Biosys. 2017, 1, 1600038
www.adv-biosys.comwww.advancedsciencenews.com
1600038 (10 of 12) © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
filtrate was collected and concentrated under a gentle stream of air for 
30 min. A large volume of cold diethyl ether was added to precipitate 
the crude peptide, which was collected after brief centrifugation (3000×g, 
5 min), washed again with diethyl ether, and dissolved in water for 
HPLC purification. 5 × 10−3 m peptide stock solutions were stored at 
4 °C until needed. For flow cytometry detection, peptide analogues were 
additionally conjugated at their N-terminus with a short PEG spacer 
(N-[8-(9-fluorenylmethyloxycarbonyl)amino-3,6-dioxaoctyl]succinamic 
acid, Ebes) and FITC dye. For both reactions, 4 molar eq. plus 8 eq. DIEA 
were mixed with beads in DMF for 2 h before washing. Reaction steps 
were confirmed by Kaiser test. For LTRS measurement, 4-(phenylbuta-
1,3-diyn-1-yl)benzoic acid (RT) was covalently conjugated to the peptide 
N-terminus via PEG spacer (Figure S1, Supporting Information) under 
similar coupling conditions. Peptide molecular weight was confirmed 
by matrix-assisted laser desorption/ionization time-of-flight (MALDI 
TOF) mass spectrometry (Bruker UltraFlextreme). Figure S1 (Supporting 
Information) displays a representative mass spectrum for purified 
LXY30-RT peptide.
Flow Cytometry: For whole cell flow cytometry, cells were trypsinized 
(if necessary) and aliquoted in 3% (v/v) FBS in PBS with LXY30-Fl or 
scr-LXY30-Fl peptide (to 1 × 10−6 m). For integrin binding, 1 µg mouse 
monoclonal anti-α3-Fl (200 µg mol−1, Santa Cruz Biotechnology, Dallas, 
TX) was added per million cells. After 30 min incubation, cells were 
washed thrice and finally resuspended with 3% FBS and 1% sodium 
azide.
On-bead flow cytometry of antibody–exosome binding was performed 
according to previous reported methods,[35] by passive adsorption to 
3.9 µm latex beads with aldehyde/sulfate groups grafted to the polymer 
surface (ThermoFisher Scientific, prod. no. A37304). Only one change to 
the protocol was made for peptide incubation: exosomes were labeled 
with peptide prior to bead adsorption. Briefly, exosomes (10 µg in 15 µL, 
as measured by BCA assay) were mixed overnight with LXY30-Fl or scr-
LXY30-Fl (1 µL, 5 × 10−3 m). Labeled exosomes were purified from free 
peptide by centrifugal spin column (ThermoFisher Scientific, MWCO: 
3000 Da, prod. no. 4484449) according to manufacturer’s instructions.
Prepared whole cells or exosome-coated latex beads were promptly 
analyzed by flow cytometry (Becton Dickinson Fortessa). Three side-by-
side replicates were performed for each condition and at least 10 000 
gated cells or beads were analyzed for each replicate. Typical gating 
strategies for SKOV-3 cells and latex beads are displayed in Figure S2 
(Supporting Information).
Laser Tweezers Raman Spectroscopy: Raman measurements were 
made on a purpose-built LTRS system that was described previously.[38] 
Briefly, 785 nm laser light (CrystalLaser, Reno, NV) was coupled into 
a 60×, 1.2 NA water immersion objective on an inverted microscope 
platform (Olympus IX-71). 25 mW of light reaches a diffraction limited 
spot with a spot size of about 1 µm. This is capable of trapping single 
exosomes and other nanoparticles, as well as larger clusters of particles. 
Raman scattered light is generated by the same laser, and this Stokes-
shifted light is collected back through the objective. It is separated from 
the primary beam through a dichroic beam splitter and edge filter (both 
Chroma Technology, Bellows Falls, VT). The Raman signal was then 
coupled into a multimode optical fiber and launched into a spectrograph 
(SpectraPro 2300i, Princeton Instruments, Trenton, NJ) and dispersed 
on a CCD (Pixis 100, Princeton Instruments).
In the experiments, five 60 s spectral frames were recorded, for 
a total of 300 s integration time, and then imported into MATLAB for 
data processing using home-brewed scripts. For the data pretreatment, 
all spectra were corrected for cosmic rays using a median threshold 
filter described previously by Beier.[54] By comparing spectra pixelwise 
across the five frames, outlier values caused by cosmic rays can be easily 
detected and their value replaced by the framewise median. The cosmic-
ray-corrected frame-level spectra were averaged to produce a single, 
300 s integration time spectrum for each sample. The spectra were then 
smoothed using the Whittaker smoother proposed by Eilers[55] with a 
Lagrange parameter of 5. After smoothing, asymmetric least squares 
(AsLS) to fit a background to the data were used. The background 
is composed of quartz, PBS buffer, and a fifth-order polynomial 
representing autofluorescence in the system. For the AsLS modeling, 
an asymmetry parameter of p = 0.001 to heavily penalize negative 
residuals was used, allowing to obtain spectra free of any background 
contamination.[38,56,57] Following background correction, all spectra 
were normalized to the area under the curve (vector normalization). 
Thus, the y-axis of the Raman spectra then represents the proportion of 
individual chemical groups relative to the total chemical content within 
the sampling volume. Instead, for comparison of absolute quantity of 
chemical content (Figure 4a), no normalization was performed.
For peptide labeling experiments, LXY30-RT or scr-LXY30 were added 
to the vesicles during imaging on the coverslip to a final concentration 
of 100 × 10−6 m. At this concentration in the absence of EVs, the notable 
peaks arising from the RT could not be discerned. To measure the 
Raman spectra for ligand alone, poorly soluble aggregates of LXY30-RT 
were trapped before full dissolution in water.
Exosome Uptake by Confocal Laser Scanning Microscopy: To label the 
membrane of EVs for cell uptake visualization, the lipophilic dye DiI 
(Life Technologies, Catalog No. D3911) was used. A stock solution 
(10 × 10−6 m) of DiI in MeOH was diluted 100-fold with SKOV-3 EVs 
(30 µg) to a final volume of 200 µL in PBS containing 0.5% BSA.[39] DiI-
labeled EVs were diluted 50-fold with McCoy’s media supplemented with 
10% EV-cleared FBS and repelleted at 100 000×g, 4 °C, 2 h. The pellet 
was resuspended in McCoy’s media. Aliquots (5 µg) DiI-labeled SKOV-3 
EVs were mixed with either LXY30 or scr-LXY30 to final concentrations of 
1 or 10 × 10−6 m. For blank controls, the peptide solution was replaced by 
PBS. After overnight incubation at 4 °C with gentle agitation, EVs were 
purified from unbound ligand by centrifugal spin column (ThermoFisher 
Scientific, MWCO: 3000 Da, prod. no. 4484449) according to 
manufacturer’s instructions.
SKOV-3 cells were plated in an eight-well ibiTreat µ-slide chambers 
(ibidi USA, Inc.) at a starting concentration of 10 000 cells per well in 
serum-containing McCoy’s media (300 µL). After 24 h, the cells were 
washed thrice with PBS and replaced with fresh media supplemented 
with 10% EV-cleared FBS. For each experimental replicate, DiI-labeled 
SKOV-3-EVs (1 µg) were added to each well. After 1 h, the cells were 
washed thrice with PBS, finally replaced in fresh PBS (200 µL), and 
promptly imaged under confocal microscopy with the appropriate 
filter set. Images were exported to ImageJ for analysis. The average 
fluorescence intensity and standard deviation (normalized by cell area) 
were measured and corrected by representative background areas. The 
statistical significance of differences in mean values was assessed using 
a two-sample independent Student’s t-test at the 99.5% confidence 
level. Differences were reported using P values.
Multiparametric Surface Plasmon Resonance: The MP-SPR Navi 200 
(BioNavis Ltd., Tampere, Finland) instrument was used for the surface 
plasmon resonance measurements. The system was equipped with 
two wavelength lasers, 670 and 785 nm, for plasmon excitation at the 
metal surface. In addition, it consisted of two independent microfluidic 
channels having inflow and outflow PEEK tubing, a controllable 
peristaltic pump for buffer flow, and a 12-port chromatography injector 
for the sample injections. Both of the channel surfaces were scanned 
with both incident wavelengths (i.e., 670 nm laser spot in flow channel 
1 and flow channel 2; 785 nm laser spot, correspondingly) over a wide 
angular area of ≈40°–78°. Such a scanning method allows for recording 
full SPR angular spectra instead of the narrow angular window near 
the SPR peak minimum that is typically measured with traditional SPR 
instruments.
The sensor surface was designed as a biofunctional multilayered 
composition whereby the bottom molecular layer consisted of a SAM 
structure. The protocol for SAM establishment on a plain gold sensor 
surface was adopted from previous works describing the robustness and 
versatility of such molecular construction.[58] In brief, the gold sensor was 
incubated overnight ex situ in a glass vial sealed with wax membrane in 
MuOH: biotin–PEG–thiol mixture in molar ratio 90%:10% in 88% EtOH. 
Immediately before using, the sensor was washed three times with 
excess amount of 99% EtOH and gently dried under nitrogen gas flow 
and mounted into the instrument. Consequently, in order to associate 
streptavidin to the biotin moieties of SAM, streptavidin solution 
Adv. Biosys. 2017, 1, 1600038
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(4 × 10−6 m) was flown over the SAM surface in situ at constant flow 
speed (20 µL min−1) in TRIS-EDTA (25 × 10−3 m TRIS, 1 × 10−3 m EDTA, 
pH 8.0) running buffer. Finally, after the streptavidin immobilization, 
using two independent microfluidic channels in the MP-SPR instrument, 
one channel surface was functionalized with biotinylated LXY30 peptide 
(LXY30-biotin) in constant TRIS-EDTA buffer flow (15 µL min−1) onto 
the gold sensor slide, while the other channel remained without LXY30 
and was exposed to only buffer flow. The interactions of three different 
concentrations of SKOV-3 exosomes with the surface-associated LXY30-
biotin were carried out using a flow speed of 10 µL min−1. Evaluation 
of interaction kinetics was performed using TraceDrawer 1.6 software 
(Ridgeview Instruments AB, Vänge, Sweden). LayerSolver 1.2.1 software 
(BioNavis Ltd., Tampere, Finland) was used for the biolayer thickness 
and refractive index modeling.
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